Ignite Creation Date:
2024-05-05 @ 11:53 AM
Last Modification Date:
2024-10-26 @ 9:15 AM
Study NCT ID:
NCT00165464
Status:
COMPLETED
Last Update Posted:
2009-04-28
First Post:
2005-09-09
Brief Title:
Taxotere Cisplatin and Irinotecan CPT-11 for Esophagogastric Cancer
Sponsor:
Dana-Farber Cancer Institute
Organization:
Dana-Farber Cancer Institute
Organization Data
Organization:
Dana-Farber Cancer Institute
Class:
OTHER
Study ID:
01-140
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Dana-Farber Cancer Institute
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
Peter C Enzinger MD
Old Organization:
Dana-Farber Cancer InstituteBrigham and Womens Hospital
Collaborators
| Name | Class |
|---|---|
| Aventis Pharmaceuticals | INDUSTRY |
| Massachusetts General Hospital | OTHER |
| Beth Israel Deaconess Medical Center | OTHER |
| Brigham and Womens Hospital | OTHER |